hoEbUEeQrnx

by Damian ⌂ @, New York, Saturday, November 17, 2018, 12:50 (61 days ago) @ DouglasCar

I do some voluntary work febrex plus pregnancy "The data for now suggest relatively similar response ratesin NSCLC (non-small cell lung cancer) for Merck's '3475,Bristol's nivolumab and Roche's MPDL3280A as singleagents," JP Morgan analyst Chris Schott said in a research note."With lung cancer representing the largest potential market forPD-1 therapy, we will closely watch how data in the spaceunfolds."


Complete thread:

 RSS Feed of thread

powered by my little forum